journal article·2024-01Open access

Loss of ESRP2 Activates TAK1‐MAPK Signaling through the Fetal RNA‐Splicing Program to Promote Hepatocellular Carcinoma Progression

Qian Yan, Xiaona Fang, Xiaoxia Liu, Sai Guo, Siqi Chen, Min Luo, Ping Lan, Xin‐Yuan Guan

Advanced Science· Volume 11· Issue 1

Abstract

Abstract Tumors usually display fetal‐like characteristics, and many oncofetal proteins have been identified. However, fetal‐like reprogramming of RNA splicing in hepatocellular carcinoma (HCC) is poorly understood. Here, it is demonstrated that the expression of epithelial splicing regulatory protein 2 (ESRP2), an RNA splicing factor, is suppressed in fetal hepatocytes and HCC, in parallel with tumor progression. By combining RNA‐Seq with splicing analysis, it is identified that ESRP2 controls the fetal‐to‐adult switch of multiple splice isoforms in HCC. Functionally, ESRP2 suppressed cell proliferation and migration by specifically switching the alternative splicing (AS) of the TAK1 gene and restraining the expression of the fetal and oncogenic isoform, TAK1_ΔE12. Notably, aberrant TAK1 splicing led to the activation of p38MAPK signaling and predicted poor prognosis in HCC patients. Further investigation revealed that TAK1_ΔE12 protein interacted closely with TAB3 and formed liquid condensation in HCC cells, resulting in p38MAPK activation, enhanced cell migration, and accelerated tumorigenesis. Loss of ESRP2 sensitized HCC cells to TAK1 kinase inhibitor (TAK1i), promoting pyroptotic cell death and CD8+ T cell infiltration. Combining TAK1i with immune checkpoint therapy achieved potent tumor regression in mice. Overall, the findings reveal a previously unexplored onco‐fetal reprogramming of RNA splicing and provide novel therapeutic avenues for HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Research and Splicing · Cancer-related molecular mechanisms research · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases Guangdong Institute of Gastroenterology The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou 510655 China

Department of General Surgery (Colorectal Surgery) The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou 510655 China

Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat‐sen University Guangzhou 510655 China

Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine Guangzhou 510060 China

Department of Pediatric Oncology, Sun Yat‐sen University Cancer Center Guangzhou 510060 China

Shenzhen Traditional Chinese Medicine Hospital Shenzhen China

Department of Clinical Oncology The University of Hong Kong‐Shenzhen Hospital Shenzhen China

Shenzhen Key Laboratory of recurrent metastatic cancer and personalized therapy The University of Hong Kong‐Shenzhen Hospital Shenzhen China

State Key Laboratory of Oncology in South China Guangzhou China

Department of Clinical Oncology State Key Laboratory for Liver Research The University of Hong Kong Hong Kong China

Advanced Energy Science and Technology Guangdong Laboratory Huizhou China

MOE Key Laboratory of Tumor Molecular Biology Jinan University Guangzhou China

Funding

National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province · National Key Research and Development Program of China · Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases

References (41)

Show source-provided references
1. 10.1038/nm.230410.1038/nm.2304 ↗
2. 10.1038/ng.12710.1038/ng.127 ↗
3. 10.3322/caac.2166010.3322/caac.21660 ↗
4. 10.1056/NEJMoa130029710.1056/NEJMoa1300297 ↗
5. 10.1016/j.cell.2020.08.04010.1016/j.cell.2020.08.040 ↗
6. Liu M. · Proc. Natl. Acad. Sci. USA · 2020 · 117 · 6113
7. 10.4161/rna.6.5.960610.4161/rna.6.5.9606 ↗
8. 10.1016/bs.ircmb.2016.06.00310.1016/bs.ircmb.2016.06.003 ↗
9. 10.1038/ncomms976810.1038/ncomms9768 ↗
10. 10.1038/s41594-018-0129-210.1038/s41594-018-0129-2 ↗
11. 10.1172/JCI13269110.1172/JCI132691 ↗
12. 10.1016/j.jhep.2021.04.03310.1016/j.jhep.2021.04.033 ↗
13. 10.1016/j.cell.2020.09.00210.1016/j.cell.2020.09.002 ↗
14. 10.1016/j.cell.2021.03.03110.1016/j.cell.2021.03.031 ↗
15. 10.1093/nar/gkv128810.1093/nar/gkv1288 ↗
16. 10.1038/1846510.1038/18465 ↗
17. 10.1038/s41388-018-0655-810.1038/s41388-018-0655-8 ↗
18. 10.1038/s41388-019-1088-810.1038/s41388-019-1088-8 ↗
19. Banani S. F. · Mol. Cell Bio. · 2017 · 18 · 285
20. 10.1016/j.celrep.2018.01.03610.1016/j.celrep.2018.01.036 ↗
21. 10.1016/j.chembiol.2017.07.01110.1016/j.chembiol.2017.07.011 ↗
22. 10.1074/jbc.M20745320010.1074/jbc.M207453200 ↗
23. 10.1084/jem.2017192210.1084/jem.20171922 ↗
24. 10.1126/science.aau281810.1126/science.aau2818 ↗
25. Malireddi R. K. S. · J. Exp. Med. · 2020 · 217
26. 10.1038/nature1859010.1038/nature18590 ↗
27. 10.1038/ncomms1412810.1038/ncomms14128 ↗
28. 10.1158/2159-8290.CD-19-067210.1158/2159-8290.CD-19-0672 ↗
29. 10.1038/3510216710.1038/35102167 ↗
30. 10.1042/EBC2022002510.1042/EBC20220025 ↗
31. 10.1016/j.canlet.2010.09.00710.1016/j.canlet.2010.09.007 ↗
32. 10.1007/s00109-022-02257-510.1007/s00109-022-02257-5 ↗
33. 10.1016/j.omtn.2021.12.02410.1016/j.omtn.2021.12.024 ↗
34. 10.7554/eLife.0895410.7554/eLife.08954 ↗
35. 10.1016/j.molcel.2009.01.02510.1016/j.molcel.2009.01.025 ↗
36. Jiang S. · eLife · 2020 · 9
37. 10.1038/s41568-022-00444-710.1038/s41568-022-00444-7 ↗
38. 10.1016/j.molcel.2022.03.03710.1016/j.molcel.2022.03.037 ↗
39. 10.7150/thno.6252110.7150/thno.62521 ↗
40. 10.1038/s41586-020-2071-910.1038/s41586-020-2071-9 ↗
41. 10.1038/s41418-020-00726-310.1038/s41418-020-00726-3 ↗